Skylar Jeremias

Investigators reported comprehensive genomic features of patients with clear cell renal cell carcinoma, potentially giving providers a better understanding of the molecular features associated with the disease.

Patients with multiple sclerosis (MS) who had a higher education level experienced less cognitive impairment related to their disease than patients with a lower education level, investigators concluded.

Misconceptions about the safety and necessity of vaccines were cited as the main reasons for lower-than-recommended vaccination rates among patients with multiple sclerosis (MS), according to new research.

Polymerase chain reaction–based comprehensive genomic profiling testing provided useful information for more than 94% of samples, including 81% of samples that normally would not have been tested, suggesting that more patients may benefit from CGP testing than anticipated.

Byooviz becomes the first FDA-approved ophthalmology biosimilar and the first FDA-approved biosimilar referencing Lucentis (ranibizumab), according to a statement from developers Samsung Bioepis and Biogen.

Investigators confirmed prognostic biomarkers for premenopausal patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, which could potentially be used to inform treatment decisions.

Non-white patients with multiple sclerosis (MS), particularly African American and Hispanic American patients, were found to experience a higher level of overall disability and more severe symptoms, highlighting current disparities in this disease.

A literature review detailed the multitude of ways that liquid biopsy can be used to aid the treatment of patients with cancer, including aiding in screening, recurrence surveillance, genomic profiling, and therapeutic decision-making.

Samsung Bioepis found during a 5-year follow-up study that Ontruzant, the company’s trastuzumab biosimilar, had comparable cardiac safety and long-term efficacy with the reference product Herceptin.

Investigators identified 5 mutated genes that could serve as biomarkers for disease prognosis and clinical outcomes associated with pancreatic ductal adenocarcinoma, a common cancer with a high mortality rate and poor prognosis.

Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.

In a survey, researchers indicated that the COVID-19 pandemic has placed extra barriers, including a lack of accessibility to patients and competing responsibilities, that have resulted in halts or delays to research on multiple sclerosis (MS) rehabilitation and quality of life.

Researchers have found that the COVID-19 pandemic has caused potentially millions of children to miss routine vaccines. During a time of back-to-school excitement and reversals of transmission prevention efforts in some states, children may be at risk of facing a slew of non-COVID-19 viral outbreaks.

Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.

Switching from Herceptin (reference trastuzumab) to trastuzumab biosimilars could significantly reduce direct medication costs attributed to breast cancer management in Saudi Arabia, researchers concluded.

Using whole genome sequencing, copy number signatures were successful in predicting both the presence of chromothripsis and clinical outcomes in patients with newly diagnosed multiple myeloma (MM).

Patients who have both multiple sclerosis (MS) and depression may have a higher risk of death and vascular disease compared with people who only have 1 or neither of those conditions.

Patients with multiple sclerosis (MS) who have recovered from COVID-19 and received the B-cell depleting therapy ocrelizumab for at least 1 year were observed to still have T-cell responses.

A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.

Foundation Medicine and Epic struck a deal to integrate comprehensive genomic profiling within Epic's electronic health records (EHRs), allowing for providers to order and review genomic profiling tests, leading to more streamlined clinical decision making.

Approximately 1 in 6 healthy individuals who underwent proactive genetic screening had genetic variants linked to increased risk for developing medically actionable disorders, including certain cancers and cardiovascular disorders.

In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), investigators concluded.

Switching patients from reference pegfilgrastim to a biosimilar could lead to substantial cost savings, with potential to offset the cost of and allow for greater access to chemotherapy treatment, investigators concluded.

Investigators examined the current bodies of evidence surrounding the emergence of next-generation gene sequencing, and the challenges that come with it, for identifying oncogenic drivers of early-stage non–small cell lung cancer (NSCLC).

Investigators found that biomarkers for neurodegeneration and inflammation could also aid providers in detecting declines in cognition and information processing speed in patients with multiple sclerosis (MS) over a 5-year period.

Use of a smartphone-based application was found to improve medication adherence and some clinical outcomes in patients managing multiple comorbidities using polypharmacy, researchers concluded.

A 2020 trends report from Artemetrx showed how biosimilar competition has contributed to lower average sales prices and claim percentages for originator products, suggesting that biosimilars are making a difference despite slow uptake.

The single-leg heel test was able to differentiate between weaker and stronger limbs in patients with multiple sclerosis (MS) and in healthy controls, suggesting that the test could prove useful for identifying impaired muscle performance.

Fear of negative emotions, lack of interest, and distrust of medical institutions were some of the reasons that participants refused to receive information regarding medically actionable secondary genetic findings, even after they received additional education on what the findings would include.

Genomic sequencing was found to be an effective way to identify and evaluate the risk of pathogenic and likely pathogenic variants detected in pediatric patients with a range of cancer types.